Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2022CancersOpen Access

Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDaniel Ruiz‐MolinaXMXiaoman MaoPAPaula Alfonso-Triguero

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ruiz‐Molina et al. (2022) studied this question.

synapsesocial.com/papers/6a1d39c843708a372d5dec5bhttps://doi.org/10.3390/cancers14194960
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease2004 · 23 citations
  2. 2iRGD Modified Chemo‐immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma2018 · 132 citations
  3. 3Problems of glioblastoma multiforme drug resistance2016 · 91 citations
  4. 4Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiforme2006 · 128 citations
  5. 5Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts2017 · 103 citations